Earnings summaries and quarterly performance for DANAHER CORP /DE/.
Executive leadership at DANAHER CORP /DE/.
Rainer Blair
Detailed
Chief Executive Officer
CEO
BE
Brian Ellis
Detailed
Senior Vice President
GC
Georgeann Couchara
Detailed
Senior Vice President, Human Resources
JG
Jose-Carlos Gutierrez-Ramos
Detailed
Senior Vice President and Chief Science Officer
MG
Matthew Gugino
Detailed
Executive Vice President and Chief Financial Officer (effective February 28, 2026)
MM
Matthew McGrew
Detailed
Executive Vice President and Chief Financial Officer
MR
Mitchell Rales
Detailed
Chairman of the Executive Committee
SR
Steven Rales
Detailed
Chairman of the Board
Board of directors at DANAHER CORP /DE/.
AS
A. Shane Sanders
Detailed
Director
AS
Alan Spoon
Detailed
Director
CL
Charles Lamanna
Detailed
Director
EZ
Elias Zerhouni
Detailed
Director
FD
Feroz Dewan
Detailed
Director
JM
Jessica Mega
Detailed
Director
JS
John Schwieters
Detailed
Director
LF
Linda Filler
Detailed
Lead Independent Director
RS
Raymond Stevens
Detailed
Director
TL
Teri List
Detailed
Director
Research analysts who have asked questions during DANAHER CORP /DE/ earnings calls.
SD
Scott Davis
Melius Research
6 questions for DHR
Also covers: CARR, DD, DOV +16 more
Vijay Kumar
Evercore ISI
6 questions for DHR
Also covers: A, ABT, AVTR +21 more
Michael Ryskin
Bank of America Merrill Lynch
5 questions for DHR
Also covers: A, ALGN, AVTR +28 more
Tycho Peterson
Jefferies
5 questions for DHR
Also covers: A, AVTR, BIO +22 more
Jack Meehan
Nephron Research LLC
4 questions for DHR
Also covers: A, AVTR, BIO +17 more
PS
Puneet Souda
Leerink Partners
4 questions for DHR
Also covers: A, ABCL, BRKR +20 more
Daniel Brennan
TD Cowen
3 questions for DHR
Also covers: A, ADPT, AVTR +24 more
Douglas Schenkel
Wolfe Research, LLC
3 questions for DHR
Also covers: A, AVTR, BRKR +21 more
Doug Schenkel
Wolfe Research LLC
3 questions for DHR
Also covers: A, AVTR, BRKR +15 more
DB
Dan Brennan
UBS
2 questions for DHR
Also covers: A, MDXH, MYGN +7 more
RV
Rachel Vatnsdal Olson
JPMorgan
2 questions for DHR
Also covers: A, ADPT, AKYA +14 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
1 question for DHR
Also covers: A, AVTR, CDXS +15 more
DL
Daniel Leonard
Stifel Financial Corp.
1 question for DHR
Also covers: A, AVTR, BIO +15 more
DL
Dan Leonard
UBS Group AG
1 question for DHR
Also covers: A, AVTR, BIO +9 more
Luke Sergott
Barclays
1 question for DHR
Also covers: A, AVTR, BRKR +19 more
MW
Michael Wriston
Bank of America
1 question for DHR
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for DHR
Also covers: A, AKYA, AVTR +11 more
Recent press releases and 8-K filings for DHR.
Danaher pre-announces Q4 beat and outlines 2026 outlook at JPM Healthcare Conference
DHR
Guidance Update
M&A
- Danaher expects Q4 2025 core revenue growth at the high end of its low single-digit guidance, with full-year adjusted EPS towards the high end of $7.70–$7.80, driven by strong consumables and equipment momentum.
- For 2026, Danaher reaffirmed targets of 3–6% core revenue growth, >100 bps adjusted operating margin expansion, and high-single-digit adjusted EPS growth.
- The company, with ~$25 billion in revenue, operates three segments (biotechnology, life sciences, diagnostics), delivers ~80% recurring revenue, ~60% gross margins, ~30% operating margins, and >$6 billion in operating cash flow.
- Danaher’s capital allocation remains biased toward disciplined M&A, evaluating targets on secular growth, defensible market positions with value reserves, and financial returns, supported by a strong balance sheet.
6 days ago
Danaher previews Q4 2025 results and 2026 guidance at JPM Conference
DHR
Guidance Update
- Q4 2025 core revenue growth expected at the high end of low-single digits and FY 2025 adjusted EPS toward the high end of the $7.70–$7.80 range
- 2026 targets: 3–6% core revenue growth, >100 bps adjusted operating margin expansion, and high-single-digit adjusted EPS growth
- 2025E segment revenues: Diagnostics ~$9.9 B, Biotechnology ~$7.3 B, Life Sciences ~$7.3 B; financial profile includes 59.5% gross margin, 28.6% adj. op. margin, and >$6 B cash flow
- New product innovations spotlight the ZenoTOF 8600 mass spectrometer, Xcellerex X-platform bioreactors, and Dxl 9000 immunoassay analyzer to drive next-generation diagnostics and biomanufacturing
6 days ago
Danaher previews Q4 2025 results and 2026 guidance at J.P. Morgan Healthcare Conference
DHR
- Danaher expects Q4 2025 core revenue growth at the high end of low-single-digit guidance and FY 2025 adjusted EPS at the upper end of the $7.70–$7.80 range.
- For 2026, Danaher targets 3%–6% core revenue growth, >100 bp expansion in adjusted operating margin, and high-single-digit adjusted EPS growth.
- The $25 billion company operates in biotechnology, life sciences, and diagnostics with ~60% gross margin, ~30% operating margin, and 80% recurring revenue.
- Long-term secular drivers include an aging global population (1.5 billion aged 65+ by 2050), over 20,000 biologics in development, and a 2.5× expansion in molecular diagnostics since 2019.
- Recent product innovations include a high-sensitivity mass spectrometer, Cytiva’s Xcellerex X-platform (3× higher oxygen transfer), and Beckman’s DxI 9000 immunoassay enabling early Alzheimer’s detection via blood.
6 days ago
Danaher previews Q4 2025 results and 2026 outlook at JPM Healthcare Conference
DHR
Guidance Update
Product Launch
- Danaher anticipates Q4 2025 core revenue growth at the high end of its low single-digit guidance, driven by high-single-digit bioprocessing consumables and mid-single-digit equipment growth; FY2025 adjusted EPS is expected at the high end of $7.70–$7.80.
- For 2026, the company projects core revenue growth of 3%–6%, adjusted operating margin expansion of over 100 bps, and adjusted EPS growth in the high single digits.
- The $25 billion portfolio spans Biotechnology, Life Sciences, and Diagnostics, delivering near 60% gross and 30% operating margins with operating cash flow exceeding $6 billion.
- Recent product launches include the ZenoTOF 7600 mass spectrometer (30× sensitivity), Xcellerex X-platform bioreactor (>3× oxygen transfer), and DxI 9000 immunoassay analyzer (100× sensitivity for early Alzheimer’s detection).
6 days ago
Danaher provides Q4 2025 performance commentary
DHR
Guidance Update
- For Q4 2025, Danaher expects revenues to increase in the mid-single digit percent range y-o-y.
- Q4 non-GAAP core revenue growth is anticipated at the high end of prior low-single digit guidance.
- FY 2025 adjusted diluted EPS expected toward the high end of the $7.70 – $7.80 range.
- CEO Rainer M. Blair highlighted strong Bioprocessing and better-than-expected Life Sciences & Diagnostics revenues in Q4 2025.
- Commentary to be delivered at the J.P. Morgan Healthcare Conference on Jan. 13, 2026 (11:15 a.m. PT) and during the Q4/FY 2025 earnings call on Jan. 28, 2026.
7 days ago
Danaher to Comment on Q4 2025 Performance
DHR
Guidance Update
Earnings
- Danaher CEO Rainer M. Blair will present on Q4 2025 results at the J.P. Morgan Healthcare Conference on Jan. 13, 2026, with a simultaneous webcast available on the company website.
- Q4 2025 revenues are estimated to increase mid-single digit percent year-over-year.
- Q4 2025 non-GAAP core revenue growth is expected toward the high-end of the company’s previously announced low-single digit guidance.
- Full year 2025 non-GAAP adjusted diluted EPS is anticipated toward the high-end of the guidance range of $7.70 to $7.80.
7 days ago
Danaher outlines 2026 growth framework at Jefferies London Healthcare Conference
DHR
Guidance Update
M&A
Product Launch
- Danaher targets 3%–6% core growth for 2026, implying high single-digit EPS expansion, following a 3% core growth and 10%+ EPS beat in Q3 2025.
- Bioprocessing revenue is expected to grow high single digits in 2026—driven by mid-teens consumables growth—while equipment sales are assumed flat after a 2025 decline.
- Diagnostics will face a $75M–$100M headwind in 2026 from volume-based procurement, but ex-China growth has been mid to high single digits, supported by new platforms like the DXI 9000 immunoanalyzer and AI-enabled digital pathology.
- Life Sciences Tools is forecast to be flattish in 2026 as academic/government exposure (~20% of the segment) remains down, offset by stable pharma, clinical and applied markets and launches such as the 8600 ZenoTOF, Mosaic Spectral solution, and Cytiva VT.
- Capital allocation remains M&A-biased under a disciplined framework—recent transactions include Abcam, Pall and GE Biopharma—with opportunistic share buybacks when ROIC justifies.
Nov 18, 2025, 11:00 AM
Danaher sets 3%-6% core growth guidance for 2026
DHR
Guidance Update
M&A
Product Launch
- Danaher ended Q3 ahead on revenue, EPS and cash flow, and plans to reinvest productivity gains in Q4; it targets 3%–6% core growth for 2026 with high single-digit EPS growth at the low end of the range.
- Bioprocessing is forecast to grow in the high single digits, led by mid-teens consumables growth, while equipment sales are assumed flat in 2026; equipment orders showed sequential improvement, with reshoring investments expected to ramp over 2027+.
- Life science tools outlook is flattish, reflecting a continued academic/government slowdown (≈20% of life sciences), offset by stable pharma, clinical and applied markets; key innovations include the 8600 ZenoTOF mass spectrometer and Mosaic Spectral flow cytometry module.
- Diagnostics ex-China has delivered mid- to high-single-digit growth over the past six quarters; the volume-based procurement headwind of $75–100 million in 2026 is easing, and new high-resolution immunoassays and AI-driven digital pathology platforms are in early rollout.
- Capital allocation remains biased toward M&A, focusing on strategic assets with “value reserves” for Danaher Business System improvement; share buybacks are opportunistic when they offer superior ROIC.
Nov 18, 2025, 11:00 AM
Danaher reports Q3 2025 results
DHR
Earnings
Guidance Update
Share Buyback
- Danaher posted $6.1 billion in Q3 2025 sales, achieving 3% core revenue growth, a 27.9% adjusted operating margin, and $1.89 adjusted EPS; generated $1.4 billion of free cash flow in the quarter.
- By segment, biotechnology revenue rose 6.5%, bioprocessing grew high-single-digit (driven by consumables), discovery & medical was up low-single-digit, and Cepheid’s installed base continued to expand globally.
- The company maintained its FY 2025 adjusted EPS guidance of $7.70–$7.80, sees Q4 core revenue growth of low-single-digit, and expects 2026 core revenue growth of 3–6% with >100 bps of margin expansion and high-single-digit EPS growth.
- Through Q3, Danaher generated $3.5 billion of free cash flow YTD (146% conversion), repurchased 10 million shares (~$2 billion), and authorized up to 35 million additional shares.
Oct 21, 2025, 12:00 PM
Danaher reports Q3 2025 results
DHR
Earnings
Guidance Update
- Revenue of $6,053 million, up 4.5% year-over-year; adjusted diluted EPS of $1.89 vs. $1.71 in Q3 2024
- Core sales growth of 3.0%, despite a 1.5% drag from currency translation
- Segment highlights: Biotechnology revenue +9.0% to $1,798 million (37.2% adjusted op margin); Life Sciences +0.5% to $1,792 million (21.0% margin); Diagnostics +4.0% to $2,463 million (29.6% margin)
- Operating cash flow of $1,662 million and free cash flow of $1,370 million for the quarter
- Q4 2025 outlook: currency expected to boost sales by ~2.5%; corporate expense ~$85 million; net interest ~$50 million; effective tax rate ~17.0%
Oct 21, 2025, 12:00 PM
Quarterly earnings call transcripts for DANAHER CORP /DE/.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more